Australian scholar Gunnell AS et al. studied the relationship between early medication use after acute myocardial infarction and long-term prognosis and showed that the risk of all-cause mortality was lowest in the group with combined beta-blockers and statins initiated within 28 days of acute myocardial infarction. The study included a total of 9580 patients aged 65-84 years with acute myocardial infarction through a longitudinal cohort study with 11 years of follow-up. The results showed that the 1-year risk of death was significantly lower with the combination than with the single agent; only patients with the combination of beta-blockers and statins (combined or not combined with ACEI/ARB) had the lowest risk of all-cause death during the 11 years of follow-up. Subgroup analysis showed that the reduced risk of all-cause death was most associated with the combination of beta-blockers and statins in male patients (HR 0.46, 95% CI 0.36 -0.58), whereas it was most associated with the combination of beta-blockers, statins, and ACEI/ARB in female patients (HR 0.77, 95% CI 0.60-0.99). (Li J. Abstract) Heart. 2013,99:1353-8.